missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-FOXO1/FOXO3 (Ser322, Ser325) Polyclonal Antibody

Description
This antibody is predicted to react with human and rat based on sequence homology.
a transcription factor of the forkhead family. A central regulator of metabolism in several cell types. May play an important role in myogenic growth and differentiation, and in the regulation of lipolysis in adipocytes by controlling the expression of adipose triglyceride lipase (ATGL), the rate-limiting lipolytic enzyme. Translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. Contains 1 fork-head domain.
Specifications
Specifications
| Antigen | Phospho-FOXO1/FOXO3 (Ser322, Ser325) |
| Applications | ELISA, Immunohistochemistry, Western Blot |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol, 0.5% BSA and 0.02% sodium azide; pH 7.4 |
| Gene | FOXO3 |
| Gene Accession No. | G3V7R4, O43524, Q12778, Q9R1E0, Q9WVH4 |
| Gene Alias | 1110048B16Rik; 2010203A17Rik; AF6q21; AF6q21 protein; AFX; AFX1; Afxh; AI876417; C76856; FKH1; Fkhr; Fkhr1; Fkhr2; Fkhrl1; FKHRL1P2; forkhead box O1; forkhead box O1a; forkhead box O1A (rhabdomyosarcoma); forkhead box O3; forkhead box O3A; forkhead box protein O1; Forkhead box protein O1A; forkhead box protein O3; forkhead homolog (rhabdomyosarcoma) like 1; Forkhead in rhabdomyosarcoma; Forkhead in rhabdomyosarcoma-like 1; forkhead protein 1; forkhead protein FKHR2; forkhead, Drosophila, homolog of, in rhabdomyosarcoma; forkhead, Drosophila, homolog of, in rhabdomyosarcoma-like 1; FOXO1; Foxo1a; FOXO2; FOXO3; Foxo3a; FOXO4; MGC120490; MLLT7 |
| Gene Symbols | FOXO1, FOXO3 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?